Neuroscience

Increased corticomotor excitability ID'd in restless legs

(HealthDay)—For patients with restless leg syndrome (RLS), the primary motor cortex (M1) exhibits hyperexcitability, which is associated with disease severity, according to a study published recently in Sleep Medicine.

Neuroscience

Brain structure linked to symptoms of restless legs syndrome

People with restless legs syndrome may have changes in a portion of the brain that processes sensory information, according to a study published in the April 25, 2018, online issue of Neurology, the medical journal of the ...

Medications

FDA approves first drug for rare form of rickets

(HealthDay)—Ultragenyx Pharmaceutical Inc.'s Crysvita (burosumab-twza) has been approved by the U.S. Food and Drug Administration to treat adults and children ages 1 year and older with x-linked hypophosphatemia (XLH).

Health

Q&A: Insomnia—what to do when you can't sleep

Dear Mayo Clinic: What is the best way to eliminate insomnia? For almost a year, I've had trouble getting much sleep. I've tried over-the-counter medications, but they aren't very effective.

page 1 from 7

Restless legs syndrome

Restless legs syndrome (RLS), also known as Wittmaack-Ekbom's syndrome, is a condition that is characterized by an irresistible urge to move one's body to stop uncomfortable or odd sensations. It most commonly affects the legs, but can also affect the arms or torso. Moving the affected body part modulates the sensations, providing temporary relief. RLS causes a sensation in the legs or arms that can most closely be compared to a burning, itching, or tickling sensation in the muscles. Some controversy surrounds the marketing of drug treatments for RLS.

This text uses material from Wikipedia, licensed under CC BY-SA